

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[CDC-561]

Announcement of Cooperative Agreement to the Association of State and Territorial Health Officials

Summary

The Centers for Disease Control and Prevention (CDC), National Immunization Program, announces the availability of fiscal year (FY) 1995 funds for a cooperative agreement with the Association of State and Territorial Health Officials (ASTHO) to identify improved methods of reaching and sustaining high immunization coverage, interrupting disease transmission, and improving vaccine preventable diseases surveillance for the States and territories. Approximately \$250,000 will be available in FY 1995 to support this project. It is expected the award will begin on or about September 15, 1995, for a 12-month budget period within a project period of 5 years. The funding estimate is subject to change.

The purposes of this immunization project are: to assure that the perspectives of State and territorial health officials are integrated into all programmatic aspects of the Childhood Immunization initiative; to provide linkage between States, private providers, and the Federal government in implementing the Vaccines for Children Program and other Federal and State vaccine initiatives; to coordinate efforts with the existing ASTHO school health project, maternal and child health programs and the existing ASTHO school health project, maternal and child health programs and the existing immunization efforts of the Association of Maternal and Child Health Programs (AMCHP), the Council of State and Territorial Epidemiologists (CSTE), and the Association for Vital Records and Health Statistics (AVRHS); and to facilitate outreach to private providers, non-profit organizations and entities involved in comprehensive school health to increase participation in the Vaccines for Children Program and other Federal and State vaccine initiatives.

In conducting activities to achieve the purpose of this program, CDC will: collaborate in the design of research protocols (e.g., Vaccines for Children (VFC) accountability studies, immunization coverage studies, random digit dialing (RDD) survey); the analysis and interpretation of data generated

from each project; and in the preparation of reports and manuscripts; provide other technical assistance in support of each project, as needed; collaborate in the planning, implementation, and evaluation of the various immunization training programs; and develop and coordinate immunization national policy and evaluation.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of Immunization and Infectious Diseases. (For ordering a copy of "Healthy People 2000," see the section **Where to Obtain Additional Information.**)

Authority

This program is authorized under section 317(k) of the Public Health Service Act, 42 U.S.C. 247b(k), as amended.

Smoke-free Workplace

PHS strongly encourages all grant recipients to provide a smoke-free workplace and to promote the nonuse of all tobacco products, and Public Law 103-277, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicant

Assistance will be provided only to ASTHO. No other applications are solicited. The Program Announcement and application kit have been sent to ASTHO. ASTHO is the most appropriate and qualified agency to conduct the activities under this cooperative agreement because ASTHO represents the chief public health official of each State and territory. Through its own membership, ASTHO has developed unique knowledge and understanding of the needs and operations of State health agencies. ASTHO members have already developed an enormous wealth of experience in immunization coverage and improving vaccine preventable diseases surveillance.

Executive Order 12372 Review

The application is not subject to review as governed by Executive Order 12372, Intergovernmental Review of Federal Programs (45 CFR Part 100).

Public Health System Reporting Requirements

This program is not subject to the Public Health System Reporting Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance Number for this program is 93.185, Immunization Research, Demonstration, Public Information, and Education, Training, and Clinical Skills Improvement Projects.

Other Requirements

Paperwork Reduction Act

Individual studies or surveys that involve the collection of information from 10 or more individuals and funded by the cooperative agreement will be subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act.

Where To Obtain Additional Information

If you are interested in obtaining additional information regarding this project, please refer to Announcement 561 and contact Carole J. Tully, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Mailstop E-09, Atlanta, Georgia 30305, telephone (404) 842-6880.

A copy of "Healthy People 2000" (Full Report, Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report, Stock No. 017-001-00473-1) referenced in the **Summary** may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: May 30, 1995.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-13627 Filed 6-2-95; 8:45 am]

BILLING CODE 4163-18-P

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A-54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443-6014.

SUPPLEMENTARY INFORMATION: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are *not* to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACCU-LAB, Inc., 405 Alderson St., Schofield, WI 54476, 800-627-8200 (formerly: Alpha Medical Laboratory, Inc., Employee Health Assurance Group, ExpressLab, Inc.).

Aegis Analytical Laboratories, Inc., 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615-331-5300.

Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/205-263-5745.

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703-802-6900.

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866.

Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787.

Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-227-2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center).

Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414-355-4444/800-877-7016.

Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5810.

Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd., Los Angeles, CA 90045, 310-215-6020.

Clinical Reference Lab, 11850 West 85th St., Lenexa, KS 66214, 800-445-6917.

CompuChem Laboratories, Inc., 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263/800-833-3984 (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group).

CompuChem Laboratories, Inc., Special Division, 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919-549-8263 (Formerly: Roche CompuChem Laboratories, Inc., Special Division, A Member of the Roche Group, CompuChem Laboratories, Inc.—Special Division).

CORNING Clinical Laboratories, South Central Division, 2320 Schuetz Rd. St. Louis, MO 63146, 800-288-7293 (formerly: Metropolitan Reference Laboratories, Inc.).

CORNING Clinical Laboratories, 8300 Esters Blvd., Suite 900, Irving, TX 75063, 800-526-0947 (formerly: Damon Clinical Laboratories, Damon/MetPath).

CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL 60191, 708-595-3888 (formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories).

CORNING MetPath Clinical Laboratories, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5000 (formerly: MetPath, Inc.).

CORNING National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 (formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science).

CORNING Nichols Institute, 7470-A Mission Valley Rd., San Diego, CA 92108-4406, 800-446-4728/619-686-3200 (formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT)).

Cox Medical Centers, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-836-3093.

Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38-H, Great Lakes, IL 60088-5223, 708-688-2045/708-688-4171.

Diagnostic Services Inc., dba DSI, 4048 Evans Ave., Suite 301, Fort Myers, FL 33901, 813-936-5446/800-735-5416.

Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-244-4468.

Drug Labs of Texas, 15201 I-10 East, Suite 125, Channelview, TX 77530, 713-457-3784.

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 800-898-0180/206-386-2672 (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).

DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310.

Eagle Forensic Laboratory, Inc., 950 N. Federal Highway, Suite 308, Pompano Beach, FL 33062, 305-946-4324.

ELSOHLY Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609.

General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267.

Harrison Laboratories, Inc., 9930 W. Highway 80, Midland, TX 79706, 800-725-3784/915-563-3300 (formerly: Harrison & Associates Forensic Laboratories).

HealthCare/MetPath, 24451 Telegraph Rd., Southfield, MI 48034, 800-444-0106, ext. 650 (formerly: HealthCare/Preferred Laboratories).

Holmes Regional Medical Center Toxicology Laboratory, 5200 Babcock St., N.E., Suite 107, Palm Bay, FL 32905, 407-726-9920.

Jewish Hospital of Cincinnati, Inc., 3200 Burnet Ave., Cincinnati, OH 45229, 513-569-2051.

LabOne, Inc., 8915 Lenexa Dr., Overland Park, Kansas 66214, 913-888-3927 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.).

Laboratory Corporation of America, 13900 Park Center Rd., Herndon, VA 22071, 703-742-3100 (formerly: National Health Laboratories Incorporated).

Laboratory Corporation of America, d.b.a. LabCorp Reference Laboratory, Substance Abuse Division, 1400 Donelson Pike, Suite A-15, Nashville, TN 37217, 615-360-3992/800-800-4522 (formerly: National Health Laboratories, Incorporated, d.b.a. National Reference Laboratory, Substance Abuse Division).

Laboratory Corporation of America, 15305 N.E. 40th St., Redmond, WA 98052, 206-882-3400 (formerly: Regional Toxicology Services).

Laboratory Corporation of America, 2540 Empire Dr., Winston-Salem, NC 27103-6710, Outside NC: 919-760-4620/800-334-8627/Inside NC: 800-642-0894 (formerly: National Health Laboratories, Incorporated).

Laboratory Corporation of America Holdings, 1120 Stateline Rd., Southaven, MS 38671, 601-342-1286 (formerly: Roche Biomedical Laboratories, Inc.).

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800-437-

4986 (formerly: Roche Biomedical Laboratories, Inc.).
 Laboratory Specialists, Inc., 113 Jarrell Dr., Belle Chasse, LA 70037, 504-392-7961.
 Marshfield Laboratories, 1000 North Oak Ave., Marshfield, WI 54449, 715-389-3734/800-222-5835.
 MedExpress/National Laboratory Center, 4022 Willow Lake Blvd., Memphis, TN 38175, 901-795-1515.
 Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43699-0008, 419-381-5213.
 Medlab Clinical Testing, Inc., 212 Cherry Lane, New Castle, DE 19720, 302-655-5227.
 MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800-832-3244/612-636-7466.
 Methodist Hospital of Indiana, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317-929-3587.
 Methodist Medical Center Toxicology Laboratory, 221 N.E. Glen Oak Ave., Peoria, IL 61636, 800-752-1835/309-671-5199.
 MetPath Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220-3610, 412-931-7200 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon).
 MetroLab-Legacy Laboratory Services, 235 N. Graham St., Portland, OR 97227, 503-413-4512, 800-237-7808(x4512).
 National Psychopharmacology Laboratory, Inc., 9320 Park W. Blvd., Knoxville, TN 37923, 800-251-9492.
 National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 805-322-4250.
 Northwest Toxicology, Inc., 1141 E. 3900 South, Salt Lake City, UT 84124, 800-322-3361.
 Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440-0972, 503-687-2134.
 Pathology Associates Medical Laboratories, East 11604 Indiana, Spokane, WA 99206, 509-926-2400.
 PDLA, Inc. (Princeton), 100 Corporate Court, So. Plainfield, NJ 07080, 908-769-8500/800-237-7352.
 PharmChem Laboratories, Inc., 1505-A O'Brien Dr., Menlo Park, CA 94025, 415-328-6200/800-446-5177.
 PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817-595-0294, (formerly: Harris Medical Laboratory).
 Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913-338-4070/800-821-3627, (formerly: Physicians Reference Laboratory Toxicology Laboratory).
 Poisonlab, Inc., 7272 Clairemont Mesa Rd., San Diego, CA 92111, 619-279-2600/800-882-7272.
 Presbyterian Laboratory Services, 1851 East Third Street, Charlotte, NC 28204, 800-473-6640.
 Puckett Laboratory, 4200 Mamie St., Hattiesburgh, MS 39402, 601-264-3856/800-844-8378.
 Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804-378-9130.

Scott & White Drug Testing Laboratory, 600 S. 25th St., Temple, TX 76504, 800-749-3788.
 S.E.D. Medical Laboratories, 500 Walter NE, Suite 500, Albuquerque, NM 87102, 505-848-8800.
 Sierra Nevada Laboratories, Inc., 888 Willow St., Reno, NV 89502, 800-648-5472.
 SmithKline Beecham Clinical Laboratories, 7600 Tyrone Ave., Van Nuys, CA 91045, 818-376-2520.
 SmithKline Beecham Clinical Laboratories, 801 East Dixie Ave., Leesburg, FL 34748, 904-787-9006, (formerly: Doctors & Physicians Laboratory).
 SmithKline Beecham Clinical Laboratories, 3175 Presidential Dr., Atlanta, GA 30340, 404-934-9205, (formerly: SmithKline Bio-Science Laboratories).
 SmithKline Beecham Clinical Laboratories, 506 E. State Pkwy., Schaumburg, IL 60173, 708-885-2010, (formerly: International Toxicology Laboratories).
 SmithKline Beecham Clinical Laboratories, 400 Egypt Rd., Norristown, PA 19403, 800-523-5447 (formerly: SmithKline Bio-Science Laboratories).
 SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214-638-1301 (formerly: SmithKline Bio-Science Laboratories).
 SmithKline Beecham Clinical Laboratories, 1737 Airport Way South, Suite 200, Seattle, WA 98134, 206-623-8100.
 South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219-234-4176.
 Southwest Laboratories, 2727 W. Baseline Rd., Suite 6, Tempe, AZ 85283, 602-438-8507.
 St. Anthony Hospital (Toxicology Laboratory), P.O. Box 205, 1000 N. Lee St., Oklahoma City, OK 73102, 405-272-7052.
 Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 314-882-1273.
 Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305-593-2260.
 TOXWORX Laboratories, Inc., 6160 Variel Ave., Woodland Hills, CA 91367, 818-226-4373 (formerly: Laboratory Specialists, Inc.; Abused Drug Laboratories; MedTox Bio-Analytical, a Division of MedTox Laboratories, Inc.).
 UNILAB, 18408 Oxnard St., Tarzana, CA 91356, 800-492-0800/818-343-8191 (formerly: MetWest-BPL Toxicology Laboratory).

No laboratories withdrew from the Program in May.

Richard Kopanda,

Acting Executive Officer, Substance Abuse and Mental Health Services Administration.
 [FR Doc. 95-13807 Filed 6-2-95; 8:45 am]

BILLING CODE 4160-20-U

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of Administration

[Docket No. N-95-3923]

Notice of Submission of Proposed Information Collection to OMB

AGENCY: Office of Administration, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments must be received within thirty (30) days from the date of this Notice. Comments should refer to the proposal by name and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Kay F. Weaver, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, Southwest, Washington, DC 20410, telephone (202) 708-0050. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Ms. Weaver.

SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35).

The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the description of the need for the information and its proposed use; (4) the agency form number, if applicable; (5) what members of the public will be affected by the proposal; (6) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (7) whether the proposal is new or an extension, reinstatement, or revision of an information collection requirement; and (8) the names and telephone numbers of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.